Pharma majors’ MS drugs safe from EU competition for years

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Pharma majors’ MS drugs safe from EU competition for years

Postby MSUK » Mon Feb 06, 2012 2:32 am

Image

Complex clinical trial designs and manufacturing steps required for biosimilars treating multiple sclerosis (MS) in Europe will likely stave off market entry for at least several years, drug consultants told Biopharm Insight.
The European Medicines Agency (EMA) recently issued draft non-clinical and clinical requirements for the development of biosimilar interferon-beta products.

The three, first-line, interferon-beta treatments approved in the EU for MS are Biogen Idec’s Avonex, Merck Serono’s Rebif and Bayer’s Betaseron; they differ with respect to their molecular structures, injection routes, dose recommendations and MS indications.

EMA requires a single, one-year trial with an MRI primary endpoint in relapsing-remitting MS (RRMS) patients as the basis for biosimilar approval. The agency further allows the results to be extrapolated to similar conditions such as clinically isolated syndrome.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2142
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service